March 28th 2024
The benefits noted in this exploratory analysis were irrespective of the number of neoadjuvant treatment cycles completed in patients with resectable non-small cell lung cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
A Focus on Acute Myeloid Leukemia
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
When to Stop Immunotherapy in Metastatic Lung Cancer: Expert Weighs In
May 27th 2020Immunotherapy should be continued for up to 2 years in patients with metastatic lung cancer who are responding to the treatment, unless they experience disease progression or excessive toxicity, according to Gilberto de Lima Lopes, MD.
Smoking Cessation Before a Lung Cancer Diagnosis Improves Outcomes
May 17th 2020People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.
FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors
April 7th 2020The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
FDA Approves Durvalumab Plus Standard of Care for SCLC
March 30th 2020The FDA approved durvalumab (Imfinzi) plus standard-of-care (SoC) chemotherapies etoposide with either carboplatin or cisplatin (platinum-etoposide) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Immunotherapy in SCLC: Results Are Promising, But Biomarkers Are Needed
March 16th 2020After nearly 4 decades of stagnation, the advent of immunotherapy has transformed the frontline treatment paradigm for patients with extensive-stage small cell lung cancer (ES-SCLC). However, biomarkers are needed to better inform which patients are most likely to respond to checkpoint inhibitors, said Jason Niu, MD, PhD.
FDA ODAC Votes on Safety and Efficacy of Ramucirumab Plus Erlotinib for EGFR+ NSCLC
February 27th 2020The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer.
FDA Grants Priority Review to Selpercatinib for Lung and Thyroid Cancer Subsets
January 31st 2020The FDA has granted a priority review designation to a new drug application (NDA) for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion–positive thyroid cancer.
FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
January 16th 2020The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Expert Talks Liquid Biopsies, Molecular Testing in Lung Cancer
January 3rd 2020Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for potential molecular drivers of their disease, explained Nathan Pennell, MD, PhD.
FDA Approves Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel for Lung Cancer Subset
December 4th 2019The FDA has approved atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) for the first-line treatment of adult patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR or ALK molecular aberrations.
FDA Grants Durvalumab Priority Review for Small Cell Lung Cancer Treatment
December 2nd 2019The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for durvalumab (Imfinzi) for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1